ValuEngine Upgrades Evogene (NASDAQ:EVGN) to Buy

Evogene (NASDAQ:EVGN) was upgraded by equities research analysts at ValuEngine from a “hold” rating to a “buy” rating in a research report issued on Thursday, ValuEngine reports.

Shares of EVGN traded down $0.01 during trading hours on Thursday, reaching $1.45. 10,900 shares of the company traded hands, compared to its average volume of 23,324. The firm has a fifty day moving average of $1.52. The company has a debt-to-equity ratio of 0.05, a quick ratio of 9.88 and a current ratio of 9.88. Evogene has a 1-year low of $1.39 and a 1-year high of $3.32.

Evogene (NASDAQ:EVGN) last announced its quarterly earnings data on Wednesday, July 31st. The biotechnology company reported ($0.16) EPS for the quarter, missing the Zacks’ consensus estimate of $0.19 by ($0.35). The company had revenue of $0.19 million for the quarter. Evogene had a negative net margin of 1,103.59% and a negative return on equity of 35.87%.

Several institutional investors and hedge funds have recently made changes to their positions in the company. Jane Street Group LLC acquired a new stake in Evogene during the 4th quarter valued at $71,000. Meitav Dash Investments Ltd. raised its stake in Evogene by 44.7% during the 1st quarter. Meitav Dash Investments Ltd. now owns 28,521 shares of the biotechnology company’s stock valued at $51,000 after purchasing an additional 8,804 shares during the period. ARK Investment Management LLC raised its stake in Evogene by 13.7% during the 1st quarter. ARK Investment Management LLC now owns 286,748 shares of the biotechnology company’s stock valued at $525,000 after purchasing an additional 34,626 shares during the period. Delek Group Ltd. raised its stake in Evogene by 4.2% during the 1st quarter. Delek Group Ltd. now owns 217,824 shares of the biotechnology company’s stock valued at $397,000 after purchasing an additional 8,717 shares during the period. Finally, Eidelman Virant Capital acquired a new stake in Evogene during the 2nd quarter valued at $102,000. 33.61% of the stock is owned by institutional investors and hedge funds.

Evogene Company Profile

Evogene Ltd., a biotechnology company, engages in developing various products for various life science markets through the use of computational predictive biology platform in the United States, Germany, and internationally. It discovers and develops products in various areas, including ag-chemicals, ag-biologicals, seed traits, integrated castor oil ag-solutions, and human microbiome-based therapeutics.

Featured Story: Cash Flow

To view ValuEngine’s full report, visit ValuEngine’s official website.

Receive News & Ratings for Evogene Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Evogene and related companies with MarketBeat.com's FREE daily email newsletter.